RT Journal Article
T1 Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
A1 Cuadrado, Antonio
A1 Llerena, Susana
A1 Cobo, Carmen
A1 Pallás, José Ramón
A1 Mateo, Miguel
A1 Cabezas, Joaquin
A1 Fortea, José Ignacio
A1 Alvarez, Silvia
A1 Pellón, Raúl
A1 Crespo, Juan
A1 Echevarría, Santiago
A1 Ayesa, Rosa
A1 Setién, Esther
A1 Lopez-Hoyos, Marcos
A1 Crespo-Facorro, Benedicto
A1 Agüero, Jesus
A1 Chueca, Natalia
A1 Garcia, Federico
A1 Calleja, Jose Luis
A1 Crespo, Javier
AB Prisons are major reservoirs of hepatitis C virus (HCV) in which a therapeutic approach has been particularly difficult so far. Our aim was to create a permanent program of HCV elimination in a prison based on a "test and treat" strategy. This open-label clinical trial was conducted in the Spanish prison "El Dueso" between May 2016 and July 2017. Viremic patients were treated with a ledipasvir-sofosbuvir regimen (8-12 weeks) according to the 2015 Spanish Guidelines. A teleconsultation program was established to follow-up patients from the hospital. Non-responders were submitted for a phylogenetic analysis and offered retreatment. An evaluation of new cases of HCV infection was performed every 6 months and upon release in all inmates. 847 (99.5%) inmates accepted to participate. HCV antibodies were present in 110 (13.0%) and 86 (10.2%) had detectable viremia. Most of them were genotype 1 or 3 (82.6%) and had  A sustained "test-and-treat" strategy against HCV in prisons is feasible and beneficial. Spreading this strategy should entail a public health impact.
YR 2018
FD 2018-06-27
LK http://hdl.handle.net/10668/12646
UL http://hdl.handle.net/10668/12646
LA en
DS RISalud
RD Apr 19, 2025